GlycoMimetics (GLYC) Set to Announce Quarterly Earnings on Wednesday

Posted by MarketBeat News on Mar 25th, 2024

GlycoMimetics (NASDAQ:GLYC – Get Free Report) is set to announce its earnings results before the market opens on Wednesday, March 27th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

GlycoMimetics Stock Up 1.7 %

GLYC stock opened at $2.93 on Monday. The stock has a market capitalization of $188.66 million, a PE ratio of -4.65 and a beta of 2.19. The firm has a 50 day moving average of $3.00 and a 200 day moving average of $2.15. GlycoMimetics has a 52 week low of $1.11 and a 52 week high of $3.53.

Institutional Investors Weigh In On GlycoMimetics

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in GlycoMimetics in the 1st quarter valued at $30,000. XTX Topco Ltd acquired a new stake in GlycoMimetics during the 2nd quarter worth $52,000. Charles Schwab Investment Management Inc. acquired a new stake in GlycoMimetics during the 4th quarter worth $68,000. Jane Street Group LLC acquired a new stake in GlycoMimetics during the 4th quarter worth $75,000. Finally, Virtu Financial LLC acquired a new stake in GlycoMimetics during the 4th quarter worth $81,000. Institutional investors and hedge funds own 55.36% of the company’s stock.

Analyst Upgrades and Downgrades

Want More Great Investing Ideas?

Several equities analysts have recently weighed in on GLYC shares. StockNews.com lowered shares of GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. Capital One Financial reaffirmed an “overweight” rating on shares of GlycoMimetics in a report on Thursday, February 22nd.

View Our Latest Stock Report on GlycoMimetics

GlycoMimetics Company Profile

(Get Free Report)

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.